Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR.In this fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords "diabetic retinopathy" and "calcium dobesilate". The extracted information included the study design, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best corrected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the findings of fluorescent angiography. 
Diabetes and its associated complications continue to be a significant health problem worldwide. Diabetic retinopathy (DR) is the major cause of vision loss and blindness in the working populations of developed countries [1] . Overall, the global rates for proliferative DR, diabetic macular edema and vision-threatening DR are 34.6%, 6.96%, 6.81% and 10.2%, respectively [2] . The DR rates in the rural and urban populations of China are 37% and 42%, respectively [3] [4] [5] .
Medical treatment can effectively halt the progression of DR, reduce its complication rate and preserve visual function [6] . Several oral medications, including aspirin [7] , protein kinase C inhibitor [8] , renin-angiotensin blockade [9] and candesartan [10] , effectively inhibit early DR lesions. Calcium dobesilate (2,5-dihydroxybenzenesulfonate) was developed for DR and chronic venous insufficiency more than 40 years ago. This vasoprotective agent was registered by the European Pharmacopoeia in 1997 and the British Pharmacopoeia in 1998 for treating DR and venous insufficiency. There are seven mechanisms by which calcium dobesilate might treat DR: (i) reducing retinal albumin leakage and capillary permeability, which protects the blood-retinal barrier (BRB) [11] ; (ii) inhibiting platelet aggregation and blood viscosity [12] ; (iii) up-regulating endothelium-dependent relaxation because of an increase in nitric oxide synthesis [13] ; (iv) inhibiting apoptosisof vascular endothelial cells in blood vessels [14] ; (v) antioxidant and antiradical activity [15] ; (vi) protecting against reactive oxygen species; or (vii) inhibiting the expression of the inflammatory and upstream VEGF regulator, ICAM-1 [16] . These pathological factors are likely the most important inducers of DR.
Calcium dobesilate remains the only angioprotective drug that reduces the progression of DR, according to several randomized clinical trials (RCTs) [17] . Until recently, there has been no global data available concerning the effectiveness of calcium dobesilate in treating DR. Therefore, we performed a meta-analysis of the RCTs that compared calcium dobesilate and placebo treatments to assess the effects of this drug and provide the best treatment regimen for patients with DR. The source materials for this analysis are publicly available.
Methods

Data sources and searches
We searched MEDLINE, Springer Link and the Cochrane Library for English-language, human-participant, randomized controlled trials (RCTs) published prior to October 31, 2013. We used the following phrases as keywords: "diabetic retinopathy", "calcium dobesilate" and relevant free terms. The Boolean operators "AND", "OR" and "NOT" were used to combine all search sets. References within the retrieved studies were examined for additional trials.
Study selection
RCTs concerning the relevant topic were selected based on the following criteria: (i) the participants were adults with DR; (ii) calcium dobesilate was used as an intervention, and a placebo or non-calcium-dobesilate treatment was used as a control; and (iii) the primary outcomes included microaneurysm, blood viscosity, hemorrhage and exudate improvements as well as capillary closure and mean changes in the visual acuity, intraocular pressure (IOP) and posterior vitreous penetration ratio (PVPR) from baseline to the end of the intervention period.
Data extraction and quality assessment
Two reviewers (XY Zhang and SS Wu) independently assessed the eligibility criteria of all studies and extracted the relevant information using EpiData Version 3.02 (Odense, Denmark). This information included the study author(s), publication year, country, sample size, study duration, intervention and control, mean change in visual acuity, blood viscosity, PVPR from baseline to the end of the intervention period, number of patients whose microaneurysms deteriorated, capillary closure, hemorrhage and exudate and methodology information. The data were sorted using Excel 2007. All discrepancies were resolved by consensus between the assessors.
The quality of the included trials was assessed using the JADAD scale for RCTs [18] , which includes an adequate method for randomization, appropriate blinding procedures and a detailed report of withdrawals and dropouts.
Data analyses
Data pooling was performed using Review Manager, Version 5.1 (Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2008). Between-group differences in the mean changes of visual acuity, blood viscosity and PVPR were expressed as weighted mean differences (WMDs; i.e., the mean change in the calcium dobesilate group minus that in the control group), with 95% confidence intervals (CIs). Risk ratios (RRs) were also calculated, with 95% CIs for the microaneurysm, capillary closure, hemorrhage and exudate improvements. The heterogeneity among studies was evaluated using the χ 2 test and I 2 statistics, and P<0.1 was considered to be significant for the heterogeneity test. A random effects model (Mantel-Haenszel) was used to calculate the estimates.
Results
Study characteristics
A total of 221 studies were initially retrieved. After excluding 57 duplicate reports, four review articles and 34 editorials, comment papers or studies that were not eligible, eight studies met our inclusion criteria and were reviewed in this meta-analysis (see Figure 1 for the study inclusion flow diagram). A total of 552 DR patients were examined among these eight studies, 306 of whom were treated with calcium dobesilate. The mean patient age ranged from 47.28 to 59.19 years old, and the mean duration of diabetes ranged from 3.6 to 15.5 years. The follow-up period ranged from 3 to 24 months. Additional study characteristics are listed in Table 1 [1926] .
Quality assessment
Generally, the quality of the included RCTs was moderate (Table 2) [1926] . Most RCTs reported the number of participants who were lost to follow-up, whereas the randomization methods used were often unclear. All studies were 
Mean changes in blood viscosity, plasmid viscosity and blood cholesterol
A random effects model was used to analyze the dependent variables according to the significant heterogeneity of three RCTs with available viscosity data. The pooled mean differences of whole blood and plasma viscosities were 0.57centipoise (CP) (95% CI: 0.75 to 0.38; P<0.001; Figure 2 ) and 0.36 CP (95% CI: 0.63 to 0.09; P=0.01; Figure 3 ).
Two RCTs reported the data on blood cholesterol reductions. The pooled mean difference of blood cholesterol reduction was 0.48 CP (95% CI: 0.640.33; P<0.00001) between calcium dobesilate and placebo groups. However, there were no significant differences in blood glyceride levels between the two groups (MD: 2.70 mg mL 1 ; 95% CI: 16.2310.83; P=0.70; Figure 4 ).
Mean visual acuity change
We used a random effects model to achieve conservative Figure 5 ).
Microaneurysm, hemorrhaging, capillary closure and exudates improvements
Microaneurysm
Three RCTs reported the number of patients whose progression deteriorated with regard to microaneurysm, and significant heterogeneity differences did not exist between these RCTs (P=0.91, I 2 =0%). We used a random effects model to pool the data and observed that the likelihood of microaneurysm improvement significantly increased in the calcium dobesilate group (RR: 0.62, 95% CI: 0.420.90, P=0.01; Figure 6 ).
Retinal hemorrhages
Two RCTs provided the improvement count data of retinal hemorrhages. No significant differences in heterogeneity were found between the two RCTs (P=0.20, I 2 =40%). A random effects model found that the risk of decreased progress toward retinal hemorrhages changed significantly (RR: 0.39, 95% CI: 0.170.88, P=0.02; Figure 7 ).
Capillary closure
Two RCTs reported the numbers of patients who demonstrated worse capillary closure progression. Significant heterogeneity was not found between these RCTs (P=0.11, I 2 =60%). A random effects model revealed that the risk of decreased progress toward capillary closure did not significantly change (RR: 0.87, 95% CI: 0.089.54, P=0.91; Figure 8 ).
Exudates
Two RCTs provided specific information concerning the improvement of retinal exudation. Significant heterogeneity was not observed between these RCTs (P=0.18, I 2 =45%). A random effects model revealed that the risk of decreased progress toward exudates changed significantly (RR: 0.31, 95% CI: 0.120.81, P=0.02; Figure 9 ). 
Study
Study type Randomization Blinding Lost to follow up Jadadscore Larsen et al. [19] RCT 1 2 1 4 Vojnikovic et al. [20] RCT 1 2 1 4 Leite et al. [21] RCT 2 2 1 5 Benarroch et al. [22] RCT 1 2 1 4 Vojnikovic et al. [23] RCT 1 2 1 4 Benarroch et al. [24] RCT 1 2 0 3 Ribeiro et al. [25] RCT 1 2 1 4 Javadzadeh et al. [26] RCT 2 2 0 4 a) DB, double blinding; RCT, randomized clinical trial; estimated effects of calcium obesilate on study characteristics, independent comparisons only (n=8). 
Reduction of the intraocular pressure
Two studies reported the reduction of IOP. Significant heterogeneity was found between these two RCTs. The pooled mean differences of IOP reduction between the two groups was 5.59 mmHg (95% CI: 6.69 to 4.50, P<0.00001; Figure 10 ).
Mean change in the function of the BRB (i.e., the PVPR)
Two RCTs reported data concerning a functional evaluation of the BRB. The pooled mean difference in PVPR was 2.77 (95% CI: 8.222.68, P=0.32; Figure 11 ).
Discussion
The results of the present systematic review suggested that an oral intake of 7502000 mg d 1 of calcium dobesilate effectively treats DR compared with placebo. Microaneurysm, exudates and retinal hemorrhages can be significantly improved; blood parameters, such as whole-blood viscosity, plasma viscosity and cholesterol, were greatly reduced to normal ranges after a 3-month treatment. This systematic review examined eight randomized, controlled studies, with a total of 552 patients. All studies fulfilled the inclusion criteria. The large sample size and randomization allocation indicate a substantial increase in statistical precision. The ratio of males to females was approximately equal. The studies were conducted in the US and Europe and involved different races and patient characteristics.
Calcium dobesilate has antioxidant, anti-radical and angioprotective properties. Furthermore, this medicine acts against the capillary permeability induced by reactive oxygen species, enhanced nitric oxide synthase activity in endothelial cells, anti-apoptotic effects in vessels and other tissues and inhibitory effects of inflammatory cytokines. Blood viscosity reductions have been well studied in vivo and in vitro. To our knowledge, this systematic review is the first to evaluate the effectiveness of calcium dobesilate among DR patients on a global basis.
Vascular leakage is a key method of evaluating the effectiveness of calcium dobesilate. The breakdown of the BRB is an early sign of vascular damage. Several methods have been applied to evaluate the function of BRB among RCTs and animal studies, including vitreous fluorophotometry [27] , PVPR [25] , vascular fragility [28] , skin capillary resistance [19, 23] and the penetration ratio [21] . Albumin leakage [29] indicates the successful treatment of capillary fragility in DR patients. Although the BRB was significantly protected in these studies, data could not be extracted or pooled together from these studies; thus, a meta-analysis could not be conducted.
Two of the eight studies showed that elevated IOP can be significantly reduced [20, 24] . However, more detailed information such as if eye drops were used to control IOP was not provided; furthermore, a large, multi-center study is warranted to confirm the conclusion.
Previous population-based studies [30, 31] have shown that hyperlipidemia is a risk factor for developing DR and for the progression of the disease. Hyperlipidemia contributes to DR and ME via endothelial dysfunction and the breakdown of the BRB, which leads to the exudation of serum lipids and lipoproteins. These effects are significantly correlated with DR severity [3234]. The RCTs examined in this paper confirmed that calcium dobesilate reduces the serum level of blood hyperglycemia; thus, this paper provides justification to prohibit the progression of DR and protect the BRB [23] .
The limitations of the current paper include the relatively small sample sizes of the analyzed studies. Furthermore, these data did not originate from multicenter, collaborative studies. A lack of detailed methods regarding the randomization procedures might increase the chances for bias and error. We also recommend that the methodological quality of clinical trials seeking to evaluate drugs be improved in the future using random allocation concealment to prevent selection bias [35] and long-term follow-up assessments that use internationally accepted, uniform and objective indicators of efficacy [36, 37] . Furthermore, the negative results, placebo control groups, number of patients lost to follow-up and lost patient records must be reported in detail [38] . 
